Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.

Sellar RS, Mehra V, Fox TA, Grigg A, Kulasekararaj A, Sarma A, de Lavallade H, McLornan D, Raj K, Mufti GJ, Pagliuca A, Mackinnon S, Chakraverty R, Fielding AK, Carpenter B, Kottaridis PD, Khwaja A, Peggs KS, Thomson KJ, Morris EC, Potter VT.

Br J Haematol. 2019 Oct;187(1):e20-e24. doi: 10.1111/bjh.16136. Epub 2019 Aug 8. No abstract available.

PMID:
31396948
2.

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.

Fox TA, Chakraverty R, Burns S, Carpenter B, Thomson K, Lowe D, Fielding A, Peggs K, Kottaridis P, Uttenthal B, Bigley V, Buckland M, Grandage V, Denovan S, Grace S, Dahlstrom J, Workman S, Symes A, Mackinnon S, Hough R, Morris E.

Blood. 2018 Feb 22;131(8):917-931. doi: 10.1182/blood-2017-09-807487. Epub 2017 Dec 26.

3.

Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.

Panagou E, Zakout G, Keshani J, Smith C, Irish D, Mackinnon S, Kottaridis P, Fielding A, Griffiths PD.

Transpl Infect Dis. 2016 Jun;18(3):405-14. doi: 10.1111/tid.12542. Epub 2016 Jun 9.

PMID:
27061703
4.

Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial.

Kottaridis PD, North J, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S, Grace S, Lowdell MW.

PLoS One. 2015 Jun 10;10(6):e0123416. doi: 10.1371/journal.pone.0123416. eCollection 2015.

5.

Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia.

Davies A, Giannoudis A, Zhang JE, Austin G, Wang L, Holyoake TL, Müller MC, Foroni L, Kottaridis PD, Pirmohamed M, Clark RE.

Clin Pharmacol Ther. 2014 Dec;96(6):694-703. doi: 10.1038/clpt.2014.176. Epub 2014 Sep 4.

PMID:
25188725
6.

Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.

Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, Kottaridis P, Grimwade D, Khwaja A, Stauss H, Morris EC.

Br J Haematol. 2014 Feb;164(3):366-75. doi: 10.1111/bjh.12637. Epub 2013 Nov 16.

7.

Does BCR/ABL1 positive acute myeloid leukaemia exist?

Nacheva EP, Grace CD, Brazma D, Gancheva K, Howard-Reeves J, Rai L, Gale RE, Linch DC, Hills RK, Russell N, Burnett AK, Kottaridis PD.

Br J Haematol. 2013 May;161(4):541-50. doi: 10.1111/bjh.12301. Epub 2013 Mar 25.

8.

The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL).

Papageorgiou SG, Cwynarski K, Kottaridis PD.

Bone Marrow Transplant. 2013 Oct;48(10):1271-8. doi: 10.1038/bmt.2012.266. Epub 2013 Jan 14. Review.

PMID:
23318539
9.

Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.

Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenberghe E, Mackinnon S, Chakraverty R.

Br J Haematol. 2013 Mar;160(5):640-8. doi: 10.1111/bjh.12197. Epub 2013 Jan 7.

PMID:
23293871
10.

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.

Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S, Liloglou T, Zhang JE, Austin G, Holyoake TL, Foroni L, Kottaridis PD, Müller MC, Pirmohamed M, Clark RE.

Blood. 2013 Jan 24;121(4):628-37. doi: 10.1182/blood-2012-01-405035. Epub 2012 Dec 5.

PMID:
23223357
11.

Preservation of fertility in women undergoing reduced-intensity conditioning allogeneic transplantation with a fludarabine-based regime.

Papageorgiou SG, Ahmed O, Narvekar N, Davies M, Kottaridis PD.

Transplantation. 2012 Sep 15;94(5):e29-30. doi: 10.1097/TP.0b013e318263ad98. No abstract available.

PMID:
22955169
12.

Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.

Katodritou E, Terpos E, North J, Kottaridis P, Verrou E, Gastari V, Chadjiaggelidou C, Sivakumaran S, Jide-Banwo S, Tsirogianni M, Kapetanos D, Zervas K, Lowdell MW.

Am J Hematol. 2011 Dec;86(12):967-73. doi: 10.1002/ajh.22163. Epub 2011 Sep 14.

13.

Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, Hough R, Morris EC, Fielding A, Chakraverty R, Thomson KJ, Mackinnon S.

J Clin Oncol. 2011 Mar 10;29(8):971-8. doi: 10.1200/JCO.2010.32.1711. Epub 2011 Jan 31.

PMID:
21282545
14.

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A, Pettengell R, Snowden J, Pettitt A, Clark R, Hale G, Peggs K, Thomson K, Morris E, Mackinnon S.

Blood. 2010 Oct 21;116(16):3080-8. doi: 10.1182/blood-2010-05-286856. Epub 2010 Jun 29.

PMID:
20587785
15.

The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation.

Knight A, Madrigal AJ, Grace S, Sivakumaran J, Kottaridis P, Mackinnon S, Travers PJ, Lowdell MW.

Blood. 2010 Sep 23;116(12):2164-72. doi: 10.1182/blood-2010-01-255166. Epub 2010 Jun 24.

PMID:
20576814
16.

Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.

Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis PD, Griffiths P, Mackinnon S, Emery V, Chakraverty R.

Transplantation. 2010 Sep 15;90(5):564-70. doi: 10.1097/TP.0b013e3181e7a3bf.

PMID:
20555307
17.

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.

Mead AJ, Thomson KJ, Morris EC, Mohamedbhai S, Denovan S, Orti G, Fielding AK, Kottaridis PD, Hough R, Chakraverty R, Linch DC, Mackinnon S, Peggs KS.

Blood. 2010 Jun 24;115(25):5147-53. doi: 10.1182/blood-2010-01-265413. Epub 2010 Apr 6.

PMID:
20371745
18.

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.

Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazón JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH.

Bone Marrow Transplant. 2011 Jan;46(1):52-8. doi: 10.1038/bmt.2010.54. Epub 2010 Mar 22.

PMID:
20305700
19.

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J, McQuaker G, Marks DI, Craddock C, McCann S, Russell N, Cook G, Kottaridis PD; British Society for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2010 Nov;45(11):1587-93. doi: 10.1038/bmt.2010.14. Epub 2010 Feb 15.

PMID:
20154739
20.

Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.

Lambert JR, Bomanji JB, Peggs KS, Thomson KJ, Chakraverty RK, Fielding AK, Kottaridis PD, Roughton M, Morris EC, Goldstone AH, Linch DC, Ell PJ, Mackinnon S.

Blood. 2010 Apr 8;115(14):2763-8. doi: 10.1182/blood-2009-11-255182. Epub 2010 Feb 2.

PMID:
20124510
21.

Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.

Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.

Transplantation. 2009 Dec 15;88(11):1312-8. doi: 10.1097/TP.0b013e3181bbf382.

PMID:
19996931
22.

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.

Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N.

Haematologica. 2010 Jun;95(6):989-95. doi: 10.3324/haematol.2009.013920. Epub 2009 Nov 30.

23.

2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.

Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Lowdell MW, Samuel ER, North JM, Nacheva EP, Chanalaris A, Kottaridis P, Cwynarski K, Wickremasinghe RG.

Blood. 2009 Aug 6;114(6):1217-25. doi: 10.1182/blood-2008-11-190587. Epub 2009 Jun 10. Erratum in: Blood. 2019 Aug 22;134(8):719-721.

PMID:
19515722
24.

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.

Goulding C, Uttenthal B, Foroni L, Duke V, Traore A, Kottaridis P, Hoffbrand AV, Patch D, McNamara C.

Int J Lab Hematol. 2008 Oct;30(5):415-9. doi: 10.1111/j.1751-553X.2007.00973.x.

PMID:
19046316
25.

The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.

Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97. doi: 10.1016/j.bbmt.2008.09.001.

26.

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.

Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Nacheva EP, Howard-Reeves JD, Duke VM, Kottaridis PD, Cwynarski K, Vassilev LT, Wickremasinghe RG.

Blood. 2008 Nov 1;112(9):3827-34. doi: 10.1182/blood-2008-05-156380. Epub 2008 Aug 5.

PMID:
18682598
27.

Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.

Mead AJ, Gale RE, Kottaridis PD, Matsuda S, Khwaja A, Linch DC.

Br J Haematol. 2008 May;141(4):454-60. doi: 10.1111/j.1365-2141.2008.07025.x. Epub 2008 Mar 12.

PMID:
18341639
28.

Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion.

Dimopoulou MN, Gandhi S, Ghevaert C, Chakraverty R, Fielding A, Webster D, Mackinnon S, Kottaridis PD.

Bone Marrow Transplant. 2007 Sep;40(6):605-6. Epub 2007 Jul 9. No abstract available.

PMID:
17618315
29.

Cardiac assessment of patients for haematopoietic stem cell transplantation.

Coghlan JG, Handler CE, Kottaridis PD.

Best Pract Res Clin Haematol. 2007 Jun;20(2):247-63. Review.

PMID:
17448960
30.

A case of 'red eye' post allogeneic stem cell transplantation.

Castleton A, Kottaridis PD.

Bone Marrow Transplant. 2007 Feb;39(4):241-2. Epub 2007 Jan 8. No abstract available.

PMID:
17211428
31.

Allogeneic stem cell transplantation as treatment for myelofibrosis.

Papageorgiou SG, Castleton A, Bloor A, Kottaridis PD.

Bone Marrow Transplant. 2006 Dec;38(11):721-7. Epub 2006 Oct 2. Review.

PMID:
17013423
32.

Diffuse bowel fluorodeoxyglucose uptake on positron emission tomography scan following allogeneic stem cell transplant.

Stewart WA, Bomanji JB, Mackinnon S, Kottaridis PD.

Br J Haematol. 2006 May;133(3):219. No abstract available.

PMID:
16643422
33.

The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro.

Steele AJ, Jones DT, Ganeshaguru K, Duke VM, Yogashangary BC, North JM, Lowdell MW, Kottaridis PD, Mehta AB, Prentice AG, Hoffbrand AV, Wickremasinghe RG.

Leukemia. 2006 Jun;20(6):1073-9.

PMID:
16628188
34.

The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation.

Delgado J, Cooper N, Thomson K, Duarte R, Jarmulowicz M, Cassoni A, Kottaridis P, Peggs K, Mackinnon S.

Biol Blood Marrow Transplant. 2006 Jan;12(1):75-83.

35.

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon E, Burnett AK, Linch DC, Grimwade D; NCRI Adult Leukaemia Working Party.

Blood. 2005 Dec 1;106(12):3768-76. Epub 2005 Aug 16.

PMID:
16105978
36.
37.

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ, Langabeer SE, Kottaridis PD, Moorman AV, Burnett AK, Linch DC.

Blood. 2005 Sep 15;106(6):2113-9. Epub 2005 Jun 9.

PMID:
15951308
38.

Syndrome 'X' in adult female recipients of bone marrow transplantation for haematological malignancies.

Chatterjee R, Palla K, McGarrigle HH, Mackinnon S, Kottaridis PD.

Bone Marrow Transplant. 2005 Jan;35(2):209-10. No abstract available. Erratum in: Bone Marrow Transplant. 2005 Feb;35(3):321. Mckinnon, S [corrected to [Mackinnon, S].

PMID:
15558043
39.

Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.

Avivi I, Chakrabarti S, Kottaridis P, Kyriaku C, Dogan A, Milligan DW, Linch D, Goldstone AH, Mackinnon S.

Bone Marrow Transplant. 2004 Jul;34(2):137-42.

PMID:
15235576
40.

The allogeneic effect in non-Hodgkin's lymphoma.

Goldstone AH, Kottaridis PD.

Leuk Lymphoma. 2003;44 Suppl 3:S91-7. Review.

PMID:
15202531
41.

Reduced intensity transplantation: where are we now?

Mackinnon S, Thomson K, Morris E, Kottaridis PD, Peggs KS.

Hematol J. 2004;5 Suppl 3:S34-8. Review. No abstract available.

PMID:
15190275
42.
43.

Flt3 mutations and leukaemia.

Kottaridis PD, Gale RE, Linch DC.

Br J Haematol. 2003 Aug;122(4):523-38. Review. No abstract available.

PMID:
12899708
44.

Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia.

Kottaridis PD, Gale RE, Linch DC.

Leuk Lymphoma. 2003 Jun;44(6):905-13. Review.

PMID:
12854887
45.

Germ cell damage and Leydig cell insufficiency in recipients of nonmyeloablative transplantation for haematological malignancies.

Kyriacou C, Kottaridis PD, Eliahoo J, McKeag N, Bomford J, McGarrigle HH, Linch DC, Mackinnon S, Chatterjee R.

Bone Marrow Transplant. 2003 Jan;31(1):45-50.

PMID:
12621506
46.

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.

Chakrabarti S, Avivi I, Mackinnon S, Ward K, Kottaridis PD, Osman H, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW.

Br J Haematol. 2002 Dec;119(4):1125-32.

PMID:
12472597
47.

Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies.

Chatterjee R, Kottaridis PD.

Bone Marrow Transplant. 2002 Nov;30(10):629-35. Review.

48.

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation.

Blood. 2002 Nov 1;100(9):3121-7.

PMID:
12384408
49.

Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.

Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, Chakraverty RK, Craddock C, Milligan DW, Pettengell R, Marsh JC, Linch DC, Goldstone AH, Williams CD, Mackinnon S.

J Clin Oncol. 2002 Oct 1;20(19):4022-31.

PMID:
12351600

Supplemental Content

Loading ...
Support Center